Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Frequently asked questions
What sector does Next Science Limited (NXSCF) operate in?
Next Science Limited belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Next Science Limited (NXSCF) current stock price?
As of the latest data, Next Science Limited stock price is $0.02, with a previous close of $0.02. Next Science Limited gained $0.00 in the last trading session, representing a 6.67% increase.
What is Next Science Limited (NXSCF) current market capitalization?
Next Science Limited market cap is approximately 4.68 million.
What is Next Science Limited (NXSCF) Earnings Per Share (EPS)?
The trailing EPS is -$0.03.
Does Next Science Limited (NXSCF) pay dividends?
No. Next Science Limited does not pay a dividend.
What is Next Science Limited (NXSCF) beta (volatility) score?
Next Science Limited has a beta of 1.692, suggesting it is more volatile than the market.